Business Wire

SIGFOX

28.2.2020 12:18:09 CET | Business Wire | Press release

Share
An Post, the Irish Leading Mails, Parcels and Ecommerce Logistics Company, Revolutionise Their Supply Chain

An Post, the leading mails, parcels and ecommerce logistics company in Ireland, has contracted VT-IoT, the operator of Ireland’s Sigfox 0G network to revolutionise their supply chain with IoT tracking devices as part of their innovative and fast-moving digital transformation strategy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200228005183/en/

As masters of delivery, An Post Mails & Parcels is rapidly changing from the old world of traditional letters to the new world of ecommerce parcel logistics and B2B services for Irish and international businesses. An Post runs Ireland’s largest fleet, including the country’s largest fleet of electric vehicles. It recently opened its new fully automated Dublin Parcel Hub and its operational infrastructure includes a large volume of returnable transport units such as roll cages and containers.

To provide an efficient and cost-effective service, An Post require a systematically integrated operational process. The roll cages and containers in which parcels are transported must be available every day in the required quantities in the Company’s mails hubs across the country.

With the advance of revolutionary Internet of Things (IoT) technology, VT and Sigfox are providing An Post with the solution they need to optimise their supply chain. Smart tracking devices empower An Post to monitor the location of their assets nationwide, even outside their own supply chain. Using Sigfox, the world’s leading IoT service provider and first global 0G network operator, has eliminated the barriers associated with traditional tracking technologies: price, battery life and coverage, by providing low cost, low power connectivity over a single global network today available in more than 70 countries.

“VT’s state-of-the-art solution has resulted in significantly increased transparency in our postal distribution network, ensuring world class quality of service for our customers and lower operational costs through improved containerisation efficiency”, explains Mark Devine, National Engineering Maintenance & Performance Manager, An Post .

“Our collaboration with An Post is an exciting step forward into the future of industrial IoT and a key milestone toward connecting billions of IoT devices globally on the Sigfox 0G network. We are confident our solutions have the power to truly revolutionise the way logistics and supply chain companies do business, resulting in significantly reduced costs and increased efficiencies .” Mark Bannon, CEO, VT.

““We are delighted to support An Post in this new era of industry 4.0, where we are making the once untraceable now entirely visible to organisations. We continue to deliver benefits to Postal organisations, like An Post in Ireland, DHL in Germany and Posti in Finland. This is a key vertical for Sigfox, where we strive to deliver value and thought leadership in Global Supply Chain & Logistics." Glen Robinson, SVP Global Sales & Marketing, Sigfox.

About An Post

An Post provides world-class mails, e-commerce parcels, financial and communications services to national and international business. It delivers two million items of mail to 2.2 million address points nationwide every working day, as well as evening and weekend parcels deliveries.

About VT

VT is a 0G IoT network operator and a pioneer of IoT solutions within the Supply Chain and Aerospace markets. Our purpose is to empower our enterprise users to transform their business models and operations through our leading-edge device to cloud 0G solutions. Our nationwide Sigfox IoT telecoms network currently delivers over 95% geographical coverage to Ireland – we are passionate about enabling every person, home and business to benefit from 0G IoT.

About Sigfox

Sigfox is the initiator of the 0G network and the world’s leading IoT (Internet of Things) service provider. Its global network allows billions of devices to connect to the Internet, in a straightforward way, while consuming as little energy as possible. Sigfox’s unique approach to device-to-cloud communications addresses the three greatest barriers to global IoT adoption: cost, energy consumption and global scalability.

Today, the network is available in 70 countries, with 1 billion people covered. ISO 9001 certified and surrounded by a large ecosystem of partners and IoT key players, Sigfox empowers companies to move their business model towards more digital services, in key areas such as Asset Tracking and Supply Chain. Founded in 2010 by Ludovic Le Moan and Christophe Fourtet, the company is headquartered in France and has offices in Madrid, Munich, Boston, Dallas, San Jose, Dubai, Singapore, Sao Paulo and Tokyo.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye